Oncology drugs and added benefit: insights from 3 European health technology assessment agencies on the role of efficacy endpoints

被引:6
作者
Smith, Nathaniel [1 ]
Fu, An-Chen [2 ]
Fisher, Tim [3 ]
Meletiche, Dennis [1 ]
Pawar, Vivek [2 ]
机构
[1] Maple Hlth Grp LLC, New York, NY USA
[2] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[3] EMD Serono Res & Dev Inst Inc, Rockland, MA USA
关键词
Reimbursement; oncology; endpoint; MARKET ACCESS; SURROGATE; AUTHORIZATION; SURVIVAL; TRIALS; NEED;
D O I
10.1080/13696998.2021.2009711
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective This study aimed to understand the impact of different efficacy endpoints on reimbursement decisions made by health technology assessment (HTA) bodies. Materials and methods European Medicines Agency (EMA) oncology product marketing authorizations were screened to identify products that completed review by 3 HTA bodies during 2016-2019: United Kingdom's National Institute for Health and Care Excellence, Germany's Gemeinsamer Bundesausschuss, and France's Haute Autorite de Sante. Each decision's endpoint information, including overall survival (OS) and progression-free survival (PFS), was extracted. Each endpoint's influence on added benefits rating (the degree of added benefit as judged by the HTA agency) and full reimbursement (i.e. reimbursed population to label) decisions was tested using bivariate analyses. Results An increasing trend was observed toward HTA submissions with immature OS data (36.8% and 71.4% in 2016 and 2019, respectively), which was a predictor of limited added benefit (p < .001). Regarding data availability, 63% of submissions provided OS, 2% provided PFS without OS; and 35% provided neither. OS availability significantly influenced added benefit (p < .001) but not full reimbursement (p > .05) decisions, whereas PFS without OS had no significant impact compared with either OS or PFS data for either outcome (p = .99). Conclusions The trend toward fewer products filing mature OS data over time suggests sponsors may be increasingly confident achieving reimbursement with surrogate endpoint data, although mature OS data provided the strongest correlation to positive reimbursement decisions. Notably, in some locally advanced settings, OS data maturity will take a long time to obtain. To expedite patient access to new medicines, payers should consider the acceptance of surrogate endpoints predictive of clinical benefit.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 22 条
  • [1] Variation in Health Technology Assessment and Reimbursement Processes in Europe
    Akehurst, Ronald L.
    Abadie, Eric
    Renaudin, Noel
    Sarkozy, Francois
    [J]. VALUE IN HEALTH, 2017, 20 (01) : 67 - 76
  • [2] Cawston H., 2018, ADJUSTMENT SUBSEQUEN
  • [3] French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends
    Chouaid, Christos
    Borget, Isabelle
    Braun, Eric
    Bazil, Marie-Laure
    Schaetz, Dominique
    Remuzat, Cecile
    Toumi, Mondher
    [J]. TARGETED ONCOLOGY, 2016, 11 (04) : 515 - 534
  • [4] Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward
    Ciani, Oriana
    Buyse, Marc
    Drummond, Michael
    Rasi, Guido
    Saad, Everardo D.
    Taylor, Rod S.
    [J]. VALUE IN HEALTH, 2017, 20 (03) : 487 - 495
  • [5] VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS
    Ciani, Oriana
    Cantrell, Anna
    Davis, Sarah
    Tappenden, Paul
    Saad, Everardo D.
    Garside, Ruth
    Buyse, Marc
    Stein, Ken
    Taylor, Rod S.
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2014, 30 (03) : 312 - 324
  • [6] A COMPARISON OF MARKET ACCESS EVALUATIONS FOR NEW ONCOLOGY THERAPIES IN FRANCE, GERMANY AND THE UK: AN ANALYSIS USING THE PRISMACCESS DATABASE
    Droeschel, D.
    de Paz, B.
    Houzelot, D.
    Walzer, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A654 - A654
  • [7] Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma
    Eichler, Hans-Georg
    Pignatti, Francesco
    Flamion, Bruno
    Leufkens, Hubert
    Breckenridge, Alasdair
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (10) : 818 - 826
  • [8] Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 2006 to 2016: A systematic analysis for the Global Burden of Disease study
    Fitzmaurice, Christina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Requirements for benefit assessment in Germany and England – overview and comparison
    Ivandic V.
    [J]. Health Economics Review, 4 (1) : 1 - 14
  • [10] Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
    Kemp, Robert
    Prasad, Vinay
    [J]. BMC MEDICINE, 2017, 15